GLP-1: Future in PsO, PsA and HS

GLP-1 receptor agonists are showing promise beyond metabolic disease, with implications for treating psoriasis, psoriatic arthritis, and hidradenitis suppurativa. This session will explore the anti-inflammatory properties of these agents and their potential roles in dermatology and rheumatology care. Faculty will highlight the latest clinical data and identify which patients may benefit most. APPs will also learn how to navigate safety concerns and patient adherence challenges.